2020
The Impact of Medications for Opioid Use Disorder on Hepatitis C Incidence Among Incarcerated Persons A Systematic Review
Seval N, Wurcel A, Gunderson CG, Grimshaw A, Springer SA. The Impact of Medications for Opioid Use Disorder on Hepatitis C Incidence Among Incarcerated Persons A Systematic Review. Infectious Disease Clinics Of North America 2020, 34: 559-584. PMID: 32782102, PMCID: PMC7437982, DOI: 10.1016/j.idc.2020.06.011.Peer-Reviewed Original Research
2019
Impact of Abstinence and of Reducing Illicit Drug Use Without Abstinence on Human Immunodeficiency Virus Viral Load
Nance RM, Trejo MEP, Whitney BM, Delaney JAC, Altice F, Beckwith CG, Chander G, Chandler R, Christopoulous K, Cunningham C, Cunningham WE, Del Rio C, Donovan D, Eron JJ, Fredericksen RJ, Kahana S, Kitahata MM, Kronmal R, Kuo I, Kurth A, Mathews WC, Mayer KH, Moore RD, Mugavero MJ, Ouellet LJ, Quan VM, Saag MS, Simoni JM, Springer S, Strand L, Taxman F, Young JD, Crane HM. Impact of Abstinence and of Reducing Illicit Drug Use Without Abstinence on Human Immunodeficiency Virus Viral Load. Clinical Infectious Diseases 2019, 70: 867-874. PMID: 30994900, PMCID: PMC7319266, DOI: 10.1093/cid/ciz299.Peer-Reviewed Original ResearchConceptsMethamphetamine/crystalViral suppressionViral loadIllicit opioidsIllicit drug useDrug useRelative viral loadHuman immunodeficiency virus (HIV) viral loadNumber of PLWHSubstance useHIV viral loadHuman immunodeficiency virusLongitudinal cohort studyHarm reduction interventionsCrystal useCocaine/crackHIV clinicCohort studyVL suppressionImmunodeficiency virusImpact of abstinenceClinical studiesHigher oddsDrug categoriesOpioids
2014
An evaluation of hepatic enzyme elevations among HIV-infected released prisoners enrolled in two randomized placebo-controlled trials of extended release naltrexone
Vagenas P, Di Paola A, Herme M, Lincoln T, Skiest DJ, Altice FL, Springer SA. An evaluation of hepatic enzyme elevations among HIV-infected released prisoners enrolled in two randomized placebo-controlled trials of extended release naltrexone. Journal Of Substance Use And Addiction Treatment 2014, 47: 35-40. PMID: 24674234, PMCID: PMC4042403, DOI: 10.1016/j.jsat.2014.02.008.Peer-Reviewed Original ResearchConceptsPlacebo-controlled trialXR-NTXGamma-glutamyl transferaseAlanine aminotransferaseMental illnessAspartate aminotransferaseRandomized placebo-controlled trialMonthly injectable formulationXR-NTX armExtended-release naltrexoneHepatic enzyme elevationHepatic enzyme levelsRelease naltrexoneAntiretroviral therapyHCV infectionBaseline characteristicsHepatic transaminasesEnzyme elevationPsychiatric medicationsHepatotoxicity concernsGlutamyl transferaseAlcohol dependenceOpioidsHIVNaltrexone